Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
precision cells
- Development stage
- Phase 2
- Lead developer
- Shanghai International Medical Center
- Modality
- Cell Therapies
- Administration
- Intravenous, Intra-arterial
01
Overview
Precision cells refer to an autologous cell-based immunotherapy platform developed by the Shanghai International Medical Center. This therapy involves the isolation of a patient's peripheral blood mononuclear cells, which are then expanded and activated ex vivo to produce a population of potent anti-tumor effector cells, typically including cytokine-induced killer (CIK) cells and natural killer (NK) cells. These activated cells are re-infused into the patient to enhance the systemic immune response against malignancies. Clinical development has focused on advanced solid tumors, specifically evaluating the safety and efficacy of these cells in combination with transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma and in combination with chemotherapy for advanced lung cancer.
- Brand names
- Precision Cells
- Other names
- Precision Cell Immunotherapy
02
Targets
pMHC (Tumor-associated and neoantigen-derived peptides presented on Major Histocompatibility Complex)
Beyond the preview
Go deeper on precision cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on precision cells.